Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2023-01-31 Report Publication Anno…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and its primary purpose is to announce the company's indicative financial calendar for the fiscal year 2023. It lists dates for the 'Résultats annuels 2022' (Annual Results), 'Assemblée générale annuelle' (Annual General Meeting), and 'Résultats semestriels 2023' (Half-year results). Since this document is an announcement *about* future financial reporting events and the AGM, rather than the full report (10-K, IR) or the AGM materials (AGM-R) themselves, it fits best as an Earnings Release (ER) if it were announcing past results, or more generally, a Report Publication Announcement (RPA) or a Regulatory Filing (RNS) if it's just a schedule. Given that it announces the schedule for the Annual Results and the AGM, and it is a press release format, it is most accurately classified as an announcement regarding the publication of reports. Since it specifically details the dates for the Annual Results and the AGM, it functions as a precursor/announcement for those events. However, the definition for ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document announces the *date* of the results, not the results themselves. The definition for RPA is 'Announcement regarding the timing, release, or publication of company reports'. This perfectly matches the content, which is the financial calendar/timing announcement. I will classify it as RPA.
2023-01-31 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité" (Semi-annual statement of the liquidity contract) and reports on the transactions (purchases and sales of shares) executed under a liquidity agreement for the second half of 2022 (2nd semestre 2022). This type of disclosure, detailing the activity of a share buyback/liquidity program, directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. Although it is a periodic report, it is not a comprehensive financial report (10-K or IR), nor is it a general earnings release (ER). It is specifically about the company's own shares transactions.
2023-01-12 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 95% confidence The document is titled 'Communiqué de presse' (Press Release) and announces two key corporate actions: the termination of a liquidity contract with one firm (Oddo BHF SCA) and the immediate implementation of a new liquidity contract with another firm (Invest Securities). It details the assets transferred and references regulatory decisions (AMF n°2021-01). While it contains significant business updates (pipeline progress for AEF0117 and AEF0217), the primary, immediate news hook is the change in market making/liquidity provision. This type of announcement, which details corporate actions, financing arrangements, or significant operational changes via a press release format, often falls under general regulatory announcements or capital/financing updates. Since the core subject is the establishment/termination of a liquidity contract, which directly impacts market trading and capital structure maintenance, 'Capital/Financing Update' (CAP) is a strong candidate. However, given that the document is a press release announcing a change in market operations/liquidity provision, which is a regulatory requirement often announced via general regulatory channels, 'Regulatory Filings' (RNS) serves as a robust category for non-standard, immediate corporate announcements that aren't core financial reports (10-K, IR, ER). Given the specific nature of liquidity contract changes, which are often mandated disclosures, RNS is the most appropriate general regulatory fallback, although CAP is also plausible. I will select RNS as the most encompassing category for this type of immediate, non-financial-reporting regulatory disclosure.
2022-12-27 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release" and announces a specific corporate event: the recruitment of the first patient for a Phase 1/2 clinical trial (AEF0217 for Down syndrome). It provides key updates on the trial timeline, scientific background, and includes quotes from the CEO and principal investigator. This format—a concise announcement of a significant operational/clinical milestone, often released to the public and regulatory bodies simultaneously—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal presentation (IP), and it is a direct announcement of a business/clinical event, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a standalone operational update. Given the context of clinical trial progress announcements, which are often mandatory disclosures but don't fit the specific financial report codes, RNS is a strong candidate. However, many companies use the ER code for any major operational update that impacts future performance, even outside of quarterly reporting. Since this is a specific, time-sensitive operational update (clinical trial recruitment start), and not a general regulatory notice, I will classify it as an Earnings Release (ER) as it functions as a major operational highlight announcement, though RNS is also plausible. Given the lack of explicit quarterly/annual financial figures, RNS is the safer, more general classification for non-standard operational news. I will select RNS as the most appropriate fallback for a press release detailing clinical trial progress.
2022-12-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a specific corporate event: the recruitment of the first patient for a Phase 1/2 clinical study (AEF0217 for Down Syndrome cognitive impairment). It provides key highlights, future timelines (study completion Q2 2023), and quotes from management and investigators. This structure—a brief, timely announcement of a significant operational/clinical milestone, rather than a comprehensive financial report (like 10-K or IR) or a transcript—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on clinical trial progress and not quarterly financial results, it is best classified as a general corporate announcement. Given the options, it is a high-level announcement of company progress. While it is not a formal Earnings Release (ER), it functions as a major operational update. However, since it is a press release announcing a clinical trial milestone, and not a regulatory filing like a 10-K or a specific report like an AR, it falls under the general category of corporate news. In the context of financial filings, press releases announcing operational progress often align closely with the function of an Earnings Release (ER) if they contain forward-looking statements and key operational metrics, or they might be classified as Regulatory Filings (RNS) if they are mandatory disclosures. Given the focus on clinical trial progress and the format of a press release, it is most accurately categorized as a general corporate announcement, which often defaults to RNS if ER is reserved strictly for financial results. Since this is a major, non-financial operational update, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER is sometimes used broadly for major company news releases. I will select RNS as the best fit for a non-financial, operational press release that doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP).
2022-12-16 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is explicitly titled 'Press release' and announces positive results from safety trials and authorization to start a new clinical trial for a drug candidate (AEF0217). It details clinical progress, safety profiles, and future trial timelines. This type of announcement, focusing on key operational and clinical milestones rather than comprehensive annual financials (10-K) or detailed management analysis (MDA), is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release detailing significant operational news (clinical trial success and regulatory approval to proceed), it fits best under the 'Earnings Release' category, which often encompasses major operational updates released outside of the formal quarterly/annual filings, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing. Given the structure and content (key highlights, CEO quote, forward-looking statements), 'ER' is the most appropriate classification for a major operational update presented as a press release. FY 2022
2022-11-15 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.